What a peptide-treatment follow-up plan should include

Record the diagnosis, relevant symptoms, existing medicines, and any measures the clinician plans to follow. A baseline allows later changes to be interpreted, though it cannot prove a treatment caused them. Ask which measure is most meaningful for the condition, rather than agreeing to every available test. FDA labeling describes outcomes studied for an approved product; a clinician must decide which of those are relevant to your situation. FDA: Labeling FAQ for prescription medicines

The plan should say when a clinician will assess response, what information you should report, and how refills are decided. “Unlimited messaging” is not the same as a planned clinical review. AHRQ advises patients to ask how they will know whether a medicine is working and what side effects need attention. Keep a record of the answer, especially if the service uses different prescribers for initial and later visits. AHRQ: Questions before taking medicine

Ask who responds to new symptoms, how quickly, and when emergency care is needed. Do not rely on a sales inbox to triage a serious reaction. If you suspect a medicine-related adverse event or a product-quality problem, FDA’s MedWatch program accepts patient reports. Reporting helps surveillance but does not replace urgent medical evaluation. Keep the product name, lot number, pharmacy, and timing available if you need to discuss a problem. FDA: Reporting serious problems

Some treatments should end when benefit is absent, risks emerge, or the diagnosis changes. Ask how to stop safely and how records will move to your regular clinician. If a service changes pharmacies or formulations, confirm the exact product again; a change can affect instructions and evidence. Shared decision-making also means revisiting the patient’s preferences and costs, not only laboratory values. AHRQ: SHARE approach

Instead of “check in later,” define what the clinician will ask: Did the symptom improve enough to matter? Did the patient experience a listed or unexpected problem? Has another medicine changed? Is the original diagnosis still plausible? A change in one laboratory value should not automatically outweigh a worse daily experience. Write the agreed measures and the next review date in the patient portal or your own notes. AHRQ: SHARE approach

Ask whether a refill requires a visit, test, or authorization and who will initiate it. If the pharmacy changes the product or form, request a clinician or pharmacist review before using the new supply. Keep the old and new labels so the difference can be explained. This is especially important when an online service, prescriber, and pharmacy are separate organizations. FDA: Labeling FAQ for prescription medicines